Paul Tudor Jones Tg Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $951,101 - $1.37 Million	-71,404 Reduced 46.22%	83,092 $1.48 Million
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $1.47 Million - $2.4 Million	112,661 Added 269.3%	154,496 $2.35 Million
Q4 2023 Feb 14, 2024	SELL	$6.68 - $18.81 $352,871 - $993,638	-52,825 Reduced 55.8%	41,835 $714,000
Q3 2023 Nov 15, 2023	BUY	$8.36 - $26.5 $791,357 - $2.51 Million	94,660 New	94,660 $791,000
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $204,923 - $376,664	44,841 New	44,841 $265,000
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $232,560 - $543,303	-15,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $98,532 - $182,995	-4,524 Reduced 22.82%	15,300 $509,000
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $644,280 - $970,583	19,824 New	19,824 $769,000
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $665,052 - $867,876	-15,983 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $403,890 - $877,466	15,983 New	15,983 $831,000
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $143,824 - $352,934	-16,160 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$7.14 - $15.99 $115,382 - $258,398	16,160 New	16,160 $159,000
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $214,408 - $295,795	-34,196 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$4.02 - $8.04 $137,467 - $274,935	34,196 New	34,196 $275,000
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $131,182 - $219,530	-17,848 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $178,480 - $226,669	17,848	17,848 $211,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.